ACXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acurx Pharmaceuticals Inc (ACXP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has shown significant recent price declines, weak financial performance, and no immediate positive catalysts. While the long-term potential of its drug pipeline exists, the delay in FDA approval and lack of strong trading signals make it unsuitable for immediate investment.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, the RSI is neutral but leaning towards oversold territory, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 2.398, with resistance levels at 3.002 and above.
The company has announced a stock purchase agreement and short-term warrants, which could raise approximately $7.1 million in capital. This funding is intended for working capital and general corporate purposes, which may support future operations.
The stock has dropped significantly (-19.68% regular market change) following the announcement of the stock offering. Additionally, the FDA approval timeline for its key drug, ibezapolstat, has been delayed to 2031, reducing near-term growth prospects. Financial performance is weak, with declining net income and EPS.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income decline of -43.26% YoY, and a significant EPS drop of -77.81% YoY. These metrics indicate poor financial health and limited profitability.
Alliance Global has lowered the price target from $20 to $10 while maintaining a Buy rating. The delay in FDA approval for ibezapolstat has negatively impacted the stock's outlook, though the new open-label Phase 2 trial could provide quicker and cheaper data.
